SLC5A2 and kidney disorder: We note the substantial difference in baseline characteristics between the SGLT2 inhibitor and sulfonylurea groups (individuals using SGLT2 inhibitors were older and had a higher burden of several comorbidities, including cardiovascular and kidney disease).